Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2003
Event Date: June 26, 2003
The filing reports a significant commercial event under Item 5 (Other Events), specifically a commitment from a major government agency for the purchase of the Company's diagnostic product.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue totals, profit margins, cash flow, debt levels, or liquidity ratios. The only specific financial figure disclosed is related to a single transaction:
- Committed Purchase Order: $2 million
- Product: OraQuick® Rapid HIV-1 Antibody Test
- Customer: Centers for Disease Control and Prevention (CDC)
Material Changes
This report does not compare current period financial results to prior periods. The material change is the announcement of a new $2 million commitment from the CDC, which represents a significant validation and revenue opportunity for the Company's flagship HIV testing product.
Outlook, Risks, and Management Commentary
Management Commentary: The Company issued a press release (Exhibit 99.1) to announce the CDC commitment. The filing incorporates this press release by reference.
Risks and Contingencies: The filing text does not explicitly detail risks, contingencies, or forward-looking guidance beyond the announcement of the CDC purchase commitment.
Key Facts for Investor Verification
- Verify the terms of the $2 million commitment from the CDC, including delivery schedules and payment terms.
- Confirm the impact of this order on the Company's revenue recognition timeline for the current fiscal period.
- Review the attached press release (Exhibit 99.1) for additional details on the scope of the CDC purchase.